Delivery Order HHSN261201200015I-HHSN26100003
Award Date 9/21/12
Potential Completion Date 3/20/15
Potential Value $599K
Federal Agency
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Philadelphia, PA 19111, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a delivery order contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services, to The Institute for Cancer Research, a non-profit research organization and subsidiary of Temple University. The $988,252 firm fixed price contract is for research and development services in the area of biomedical basic research, specifically preclinical efficacy and biomarker analysis to support the NCI's PREVENT Cancer Preclinical Drug Development Program....
- This is a $547,860 delivery order contract awarded by the National Cancer Institute (NCI) of the Department of Health and Human Services (HHS) to The Institute for Cancer Research, a non-profit research organization. The contract is part of the Preclinical Efficacy and Intermediate Endpoint Biomarkers indefinite delivery vehicle, which supports the PREVENT Cancer Preclinical Drug Development Program. Under this 5-year IDIQ, The Institute for Cancer Research provides preclinical efficacy...
- The National Cancer Institute awarded a firm fixed-price delivery order valued at $1,038,958 to The Institute For Cancer Research (ICR), a non-profit subsidiary of Temple University, on July 10, 2023, for research on colorectal cancer prevention using urolithin A in rodent cancer models. The work will be performed in Philadelphia, Pennsylvania, with a completion date of July 9, 2027. This task order was issued without set-aside designation and falls under ICR's larger $149.995 million Indefinite...
- The Institute For Cancer Research, a non-profit subsidiary of Temple University, has been awarded a $884,185.34 firm fixed price delivery order against the National Cancer Institute's PREVENT Cancer Program multiple award indefinite delivery contract vehicle. This delivery order focuses on continued evaluation of candidate chemopreventive and immunopreventive regimens in support of the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS through January...
- The Institute For Cancer Research (ICR), a non-profit subsidiary of Temple University, was awarded a $779,932 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program (PREVENT) multiple award master indefinite delivery contract held by the National Cancer Institute. The delivery order, with a completion date of March 2025, will fund continued evaluation of candidate chemopreventive and immunopreventive regimens to support the goals of the PREVENT program in...
- The National Cancer Institute (NCI) awarded a firm fixed-price delivery order valued at $2.05M to The Institute for Cancer Research (ICR), a non-profit subsidiary of Temple University, on June 15, 2022. This task order, which extends through May 14, 2026, supports the development of vaccines against Fusobacterium for colorectal cancer immunoprevention in patients with familial adenomatous polyposis (FAP) and Lynch syndrome. The work will be performed at ICR's facility in Philadelphia,...
- The National Cancer Institute awarded a $68,323 firm fixed-price delivery order to IIT Research Institute (IITRI) for toxicology studies in mice administered MTX-531, with a final completion date of May 9, 2026. This delivery order, which carries no set-aside designation, represents work performed under one of IITRI's larger Indefinite Delivery/Indefinite Quantity (IDIQ) vehicles—the $149.995 million PREVENT Cancer Preclinical Drug Development Program with the National Cancer Institute. The work...
- This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The $4,145 contract is for a pre-clinical toxicology study of a drug developed for cancer patients, as part of the Toxicology of Drugs Developed for Cancer Patients contract vehicle. IITRI specializes in preclinical drug development services and has...
- The National Cancer Institute issued a delivery order to The Institute For Cancer Research on September 15, 2022, under the PREVENT Preclinical Drug Development Program (PREVENT) IDIQ for preclinical efficacy and intermediate endpoint biomarker studies supporting a nano-drug for colon cancer prevention, with a ceiling value of $1.57 million and ultimate completion date of June 14, 2026. PREVENT is a National Cancer Institute IDIQ structured around three technical pools: Preclinical Efficacy...
- The National Cancer Institute issued a delivery order to Sri International on May 10, 2018, with a ceiling value of $212,246.94, under the Toxicology of Drugs Developed for Cancer Patients IDIQ for a tissue cross-reactivity study of a human antibody in support of next-generation anti-CFH AB (CBAB1) development. Place of performance is Menlo Park, CA. The order is priced on a cost-plus-fixed-fee basis with an ultimate completion date of March 31, 2019. Sri International, a non-profit research and...